Scientists have used pharmacological inhibitors of polycomb proteins to restore the expression of tumor suppressor genes and stop cancer proliferation and invasion. A major limitation of this approach is that key transcriptional activators, such as TP53 and BAF SWI/SNF, are often mutated in cancer. Poor clinical results for polycomb-targeting therapies in solid cancers, including triple-negative breast cancer (TNBC), could discourage the further development of epigenetic monotherapies. Here, we performed epigenome actuation with a synthetic reader-actuator (SRA) that binds trimethylated histone H3 lysine 27 in polycomb chromatin and modulates core transcriptional activators. In SRA-expressing TNBC BT-549 cells, 122 genes become upregulated ≥2-fold, including the genes involved in cell death, cell cycle arrest, and migration inhibition. The SRA-expressing spheroids showed reduced size in Matrigel and loss of invasion. Therefore, targeting Mediator-recruiting regulators to silenced chromatin can activate tumor suppressors and stimulate anti-cancer phenotypes, and further development of robust gene regulators might benefit TNBC patients.
Get full access to this article
View all access options for this article.
References
1.
AhujaN, SharmaAR, BaylinSB. Epigenetic therapeutics: A new weapon in the war against cancer. Annu Rev Med, 2016; 67:73–89; doi: 10.1146/annurev-med-111314-035900
2.
BernsteinE, DuncanEM, MasuiO, et al.Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol, 2006; 26(7):2560–2569; doi: 10.1128/MCB.26.7.2560-2569.2006
3.
GounderM, SchöffskiP, JonesRL, et al.Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: An international, open-label, phase 2 basket study. Lancet Oncol, 2020; 21(11):1423–1432; doi: 10.1016/S1470-2045(20)30451-4
4.
StuckeyJI, DicksonBM, ChengN, et al.A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nat Chem Biol, 2016; 12(3):180–187; doi: 10.1038/nchembio.2007
5.
LiZ, CaoR, WangM, et al.Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem, 2006; 281(29):20643–20649; doi: 10.1074/jbc.M602461200
6.
JinN, GeorgeTL, OttersonGA, et al.Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics, 2021; 13(1):83; doi: 10.1186/s13148-021-01069-7
KleerCG, CaoQ, VaramballyS, et al.EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A, 2003; 100(20):11606–11611; doi: 10.1073/pnas.1933744100
9.
RaaphorstFM, MeijerCJLM, FieretE, et al.Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia, 2003; 5(6):481–488; doi: 10.1016/s1476-5586(03)80032-5
10.
BachmannIM, HalvorsenOJ, CollettK, et al.EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol, 2006; 24(2):268–273; doi: 10.1200/JCO.2005.01.5180
11.
ChienY-C, LiuL-C, YeH-Y, et al.EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res, 2018; 8(3):422–434.
12.
CollettK, EideGE, ArnesJ, et al.Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res, 2006; 12(4):1168–1174; doi: 10.1158/1078-0432.CCR-05-1533
13.
HolmK, GrabauD, LövgrenK, et al.Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol, 2012; 6(5):494–506; doi: 10.1016/j.molonc.2012.06.002
14.
Al-MahmoodS, SapiezynskiJ, GarbuzenkoOB, et al.Metastatic and triple-negative breast cancer: Challenges and treatment options. Drug Deliv Transl Res, 2018; 8(5):1483–1507; doi: 10.1007/s13346-018-0551-3
15.
LiedtkeC, MazouniC, HessKR, et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008; 26(8):1275–1281; doi: 10.1200/JCO.2007.14.4147
16.
HowardFM, OlopadeOI. Epidemiology of triple-negative breast cancer: A review. Cancer J, 2021; 27(1):8–16; doi: 10.1097/PPO.0000000000000500
17.
DietzeEC, SistrunkC, Miranda-CarboniG, et al.Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer, 2015; 15(4):248–254; doi: 10.1038/nrc3896
18.
SiddharthS, SharmaD. Racial disparity and triple-negative breast cancer in African-American women: A multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers, 2018; 10(12); doi: 10.3390/cancers10120514
19.
LundMJ, ButlerEN, HairBY, et al.Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: A population-based study and first report. Cancer, 2010; 116(11):2549–2559; doi: 10.1002/cncr.25016
20.
Jene-SanzA, VáraljaiR, VilkovaAV, et al.Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol, 2013; 33(19):3951–3961; doi: 10.1128/MCB.00426-13
21.
YomtoubianS, LeeSB, VermaA, et al.Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer. Cell Rep, 2020; 30(3):755–770.e6; doi: 10.1016/j.celrep.2019.12.056
22.
KingHW, FursovaNA, BlackledgeNP, et al.Polycomb repressive complex 1 shapes the nucleosome landscape but not accessibility at target genes. Genome Res, 2018; 28(10):1494–1507; doi: 10.1101/gr.237180.118
23.
HodgesHC, StantonBZ, CermakovaK, et al.Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. Nat Struct Mol Biol, 2018; 25(1):61–72; doi: 10.1038/s41594-017-0007-3
24.
LehmannBD, ColapricoA, SilvaTC, et al.Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun, 2021; 12(1):6276; doi: 10.1038/s41467-021-26502-6
25.
LeeM-S, LimK, LeeM-K, et al.Structural basis for the interaction between p53 transactivation domain and the mediator subunit MED25. Molecules, 2018; 23(10); doi: 10.3390/molecules23102726
26.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012; 490(7418):61–70; doi: 10.1038/nature11412
27.
WasielewskiM, ElstrodtF, KlijnJGM, et al.Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat, 2006; 99(1):97–101; doi: 10.1007/s10549-006-9186-z
28.
KiaSK, GorskiMM, GiannakopoulosS, et al.SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol, 2008; 28(10):3457–3464; doi: 10.1128/MCB.02019-07
29.
WangL, BaiocchiRA, PalS, et al.The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol, 2005; 25(18):7953–7965; doi: 10.1128/MCB.25.18.7953-7965.2005
30.
TekelSJ, VargasDA, SongL, et al.Tandem histone-binding domains enhance the activity of a synthetic chromatin effector. ACS Synth Biol, 2018; 7(3):842–852; doi: 10.1021/acssynbio.7b00281
31.
VojnicE, MourãoA, SeizlM, et al.Structure and VP16 binding of the Mediator Med25 activator interaction domain. Nat Struct Mol Biol, 2011; 18(4):404–409; doi: 10.1038/nsmb.1997
32.
MalikS, RoederRG. The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet, 2010; 11(11):761–772; doi: 10.1038/nrg2901
33.
NyerDB, DaerRM, VargasD, et al.Regulation of cancer epigenomes with a histone-binding synthetic transcription factor. NPJ Genom Med, 2017; 2; doi: 10.1038/s41525-016-0002-3
34.
OlneyKC, NyerDB, VargasDA, et al.The synthetic histone-binding regulator protein PcTF activates interferon genes in breast cancer cells. BMC Syst Biol, 2018; 12(1):83; doi: 10.1186/s12918-018-0608-4
35.
NakajimaW, MiyazakiK, AsanoY, et al.Krüppel-Like Factor 4 and its activator APTO-253 induce NOXA-mediated, p53-independent apoptosis in triple-negative breast cancer cells. Genes, 2021; 12(4); doi: 10.3390/genes12040539
36.
SunS, WuH, WuX, et al.Silencing of PGK1 promotes sensitivity to paclitaxel treatment by upregulating XAF1-mediated apoptosis in triple-negative breast cancer. Front Oncol, 2021; 11:535230; doi: 10.3389/fonc.2021.535230
37.
IbnatN, KamaruzmanNI, AshaieM, et al.Transfection with p21 and p53 tumor suppressor plasmids suppressed breast tumor growth in syngeneic mouse model. Gene, 2019; 701; doi: 10.1016/j.gene.2019.02.082
38.
HuntKK, WingateH, YokotaT, et al.Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res, 2013; 15(1):R3; doi: 10.1186/bcr3374
39.
PopedaM, MarkiewiczA, StokowyT, et al.Reduced expression of innate immunity-related genes in lymph node metastases of luminal breast cancer patients. Sci Rep, 2021; 11(1):5097; doi: 10.1038/s41598-021-84568-0
40.
BanhRS, IorioC, MarcotteR, et al.PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. Nat Cell Biol, 2016; 18(7):803–813; doi: 10.1038/ncb3376
41.
ErnstJ, KheradpourP, MikkelsenTS, et al.Mapping and analysis of chromatin state dynamics in nine human cell types. Nature, 2011; 473(7345):43–49; doi: 10.1038/nature09906
42.
ThapaRJ, NogusaS, ChenP, et al.Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci U S A, 2013; 110(33):E3109–E3118; doi: 10.1073/pnas.1301218110
43.
KaiserWJ, SridharanH, HuangC, et al.Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem, 2013; 288(43):31268–31279; doi: 10.1074/jbc.M113.462341
44.
SeifertL, MillerG. Molecular pathways: The Necrosome-A target for cancer therapy. Clin Cancer Res, 2017; 23(5):1132–1136; doi: 10.1158/1078-0432.CCR-16-0968
45.
HanJ, GoldsteinLA, HouW, et al.Functional linkage between NOXA and Bim in mitochondrial apoptotic events. J Biol Chem, 2007; 282(22):16223–16231; doi: 10.1074/jbc.M611186200
46.
LaBaerJ, GarrettMD, StevensonLF, et al.New functional activities for the p21 family of CDK inhibitors. Genes Dev, 1997; 11(7):847–862; doi: 10.1101/gad.11.7.847
47.
DingW, FanX-L, XuX, et al.Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer. PLoS One, 2015; 10(8):e0135128; doi: 10.1371/journal.pone.0135128
48.
GeoffroyM, KleinclaussA, KuntzS, et al.Claudin 1 inhibits cell migration and increases intercellular adhesion in triple-negative breast cancer cell line. Mol Biol Rep, 2020; 47(10):7643–7653; doi: 10.1007/s11033-020-05835-3
49.
Adorno-CruzV, HoffmannAD, LiuX, et al.ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes Dis, 2021; 8(4):493–508; doi: 10.1016/j.gendis.2020.01.015
50.
LehmannBD, BauerJA, ChenX, et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011; 121(7):2750–2767; doi: 10.1172/JCI45014
51.
ZhaoM, KimP, MitraR, et al.TSGene 2.0: An updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res, 2016; 44(D1):D1023–D1031; doi: 10.1093/nar/gkv1268
52.
MaharaS, LeePL, FengM, et al.HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci U S A, 2016; 113(26):E3735–E3744; doi: 10.1073/pnas.1602079113
53.
ShieldsCE, SchneppRW, HaynesKA. Differential epigenetic effects of BMI inhibitor PTC-028 on fusion-positive rhabdomyosarcoma cell lines from distinct metastatic sites. Regen Eng Transl Med, 2022; doi: 10.1007/s40883-021-00244-9
54.
ShieldsCE, PotlapalliS, Cuya-SmithSM, et al.Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Mol Oncol, 2021; 15(8):2156–2171; doi: 10.1002/1878-0261.12914
55.
ThomasPD, EbertD, MuruganujanA, et al.PANTHER: Making genome-scale phylogenetics accessible to all. Protein Sci, 2022; 31(1):8–22; doi: 10.1002/pro.4218
56.
HirukawaA, SmithHW, ZuoD, et al.Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nat Commun, 2018; 9(1):2547; doi: 10.1038/s41467-018-04864-8
57.
LiuJ-Y, JiangY-N, HuangH, et al.BMI-1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes. Cancer Sci, 2023; 114(2):449–462; doi: 10.1111/cas.15623
NathA, OakA, ChenKY, et al.Palmitate-induced IRE1-XBP1-ZEB signaling represses desmoplakin expression and promotes cancer cell migration. Mol Cancer Res, 2021; 19(2):240–248; doi: 10.1158/1541-7786.MCR-19-0480
60.
ZhaoD, QiaoJ, HeH, et al.TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway. Mol Med, 2020; 26(1):27; doi: 10.1186/s10020-020-00158-2
61.
StephenHM, KhouryRJ, MajmudarPR, et al.Epigenetic suppression of neprilysin regulates breast cancer invasion. Oncogenesis, 2016; 5:e207; doi: 10.1038/oncsis.2016.16
62.
ShimoT, KubotaS, YoshiokaN, et al.Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res, 2006; 21(7):1045–1059; doi: 10.1359/jbmr.060416
63.
WangS-P, TangZ, ChenC-W, et al.A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription. Mol Cell, 2017; 67(2):308–321.e6; doi: 10.1016/j.molcel.2017.06.028
64.
MorinRD, ArthurSE, AssoulineS. Treating lymphoma is now a bit EZ-er. Blood Adv, 2021; 5(8):2256–2263; doi: 10.1182/bloodadvances.2020002773.
65.
ShiB, LiangJ, YangX, et al.Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol, 2007; 27(14):5105–5119; doi: 10.1128/MCB.00162-07
66.
LeeST, LiZ, WuZ, et al.Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell, 2011; 43(5):798–810; doi: 10.1016/j.molcel.2011.08.011
67.
ChanHL, BeckedorffF, ZhangY, et al.Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms. Nat Commun, 2018; 9(1):3377; doi: 10.1038/s41467-018-05728-x
68.
TanJ, YangX, ZhuangL, et al.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev, 2007; 21(9):1050–1063; doi: 10.1101/gad.1524107
69.
OmachiK, MinerJH. Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation. PLoS One, 2022; 17(6):e0270008; doi: 10.1371/journal.pone.0270008
70.
LangmeadB, SalzbergSL. Fast gapped-read alignment with Bowtie 2. Nat Methods, 2012; 9(4):357–359; doi: 10.1038/nmeth.1923
BuenrostroJD, GiresiPG, ZabaLC, et al.Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods, 2013; 10(12):1213–1218; doi: 10.1038/nmeth.2688
73.
JungYH, KremskyI, GoldHB, et al.Maintenance of CTCF- and transcription factor-mediated interactions from the gametes to the early mouse embryo. Mol Cell, 2019; 75(1):154–171.e5; doi: 10.1016/j.molcel.2019.04.014
74.
LyuX, RowleyMJ, CorcesVG. Architectural proteins and pluripotency factors cooperate to orchestrate the transcriptional response of hESCs to temperature stress. Mol Cell, 2018; 71(6):940–955.e7; doi: 10.1016/j.molcel.2018.07.012
75.
JungYH, SauriaMEG, LyuX, et al.Chromatin states in mouse sperm correlate with embryonic and adult regulatory landscapes. Cell Rep, 2017; 18(6):1366–1382; doi: 10.1016/j.celrep.2017.01.034
76.
LiuT. Use model-based analysis of ChIP-Seq (MACS) to analyze short reads generated by sequencing protein–DNA interactions in embryonic stem cells. In: Stem Cell Transcriptional Networks: Methods and Protocols. (Kidder BL. ed.) Springer New York: New York, NY;, 2014; pp. 81–95; doi: 10.1007/978-1-4939-0512-6_4
77.
AmemiyaHM, KundajeA, BoyleAP. The ENCODE Blacklist: Identification of problematic regions of the genome. Sci Rep, 2019; 9(1):9354; doi: 10.1038/s41598-019-45839-z
HaynesKA, PriodeJH. Rapid single-pot assembly of modular chromatin proteins for epigenetic engineering. Methods Mol Biol, 2023; 2599:191–214; doi: 10.1007/978-1-0716-2847-8_14
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
